CITY OF INDUSTRY, Calif., Jan. 5 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. has retained Dr. Martha Farmer as consultant for technical communications of its current initiatives. Dr. Farmer will help to guide us through FDA applications and clinical development of our current technologies.
“I’m pleased to be a member of the U.S. BioDefense team; the technologies under development have enormous potential,” said Dr. Farmer.
Dr. Martha C. Farmer earned her Ph.D. in Physiology and Pharmacology at Duke University. She holds three patents related to liposome encapsulation and hemoglobin-based oxygen carriers and is the author of more than thirty publications in those fields.
She has eighteen years of industry experience in blood products and biopharmaceutical development, primarily at Baxter Healthcare where her responsibilities evolved from laboratory management to business development, marketing and communications director positions. For the last several years she has been an independent consultant in technical communications, clinical development, bioethics and regulatory affairs both for start-ups and publicly held biotech and pharmaceutical companies. She is a member of the American Society of Hematology.
“We are excited to have Dr. Farmer join our accomplished team. Her strong laboratory background and knowledge of the regulatory process makes her the best candidate to lead our team through clinical development,” said David Chin, CEO. “We are confident that with her guidance, we can move our company forward towards therapeutic developments.”
Safe Harbor Statement
Included in this release are certain “forward-looking” statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding U.S. BioDefense’s financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to U.S. BioDefense’s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in U.S. BioDefense’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact: U.S. BioDefense, Inc. David Chin 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.
CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
